Cytotoxic T lymphocyte associated antigen 4 expression predicts poor prognosis in luminal B HER2-negative breast cancer

  • Authors:
    • Gaochen Lan
    • Jie Li
    • Qiaomei Wen
    • Lin Lin
    • Libin Chen
    • Liyu Chen
    • Xi Chen
  • View Affiliations

  • Published online on: February 7, 2018     https://doi.org/10.3892/ol.2018.7991
  • Pages: 5093-5097
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Cytotoxic T lymphocyte associated antigen 4 (CTLA‑4) serves an important role in inhibiting anti‑tumor immune response in the majority of solid tumors. However, a limited number of studies reported the function of CTLA‑4 in luminal B HER2‑negative breast cancer. Immunohistochemistry was performed to evaluate the expression of tumor and interstitial CTLA‑4 in luminal B HER2‑negative breast cancer tissues. The percentage of patients with tumor and interstitial CTLA‑4+ was 41.2% (42/102) and 46.1% (47/102), respectively. There was a positive association between tumor CTLA‑4 expression and interstitial CTLA‑4 expression (P<0.05). The disease‑free survival (DFS) of the tumor CTLA‑4+ group was significantly shorter compared with patients with tumor CTLA‑4‑ (mean, 89.070 vs. 39.022 months; P<0.0001). Additionally, the DFS of interstitial CTLA‑4+ group was shorter compared with the interstitial CTLA‑4‑ group (mean, 85.526 vs. 46.574 months; P<0.0001). Tumor and interstitial CTLA‑4 expression may have prognostic predicting value in luminal B HER2‑negative breast cancer. The present study may provide the basis for the use of a CTLA‑4 blocker in patients with luminal B HER2‑negative breast cancer.

References

1 

DeSantis C, Ma J, Bryan L and Jemal A: Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014. View Article : Google Scholar : PubMed/NCBI

2 

Siegel R, Miller K and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI

3 

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI

4 

Zhang ML, Huang ZZ and Zheng Y: Estimates and prediction on indidence, mortality and prevalence of breast cancer in China, 2008. Zhonghua Liu Xing Bing Xue Za Zhi. 33:1049–1051. 2012.(In Chinese). PubMed/NCBI

5 

Cancer Genome Atlas Network, . Comprehensive molecular portraits of human breast tumors. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI

6 

Si W, Li Y, Han Y, Zhang F, Wang Y, Li Y, Linghu RX, Zhang X and Yang J: Epidemiological and clinicopathological trends of breast cancer in chinese patients during 1993 to 2013: A retrospective study. Medicine (Baltimore). 94:e8202015. View Article : Google Scholar : PubMed/NCBI

7 

Tran B and Bedard PL: Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res. 13:2212011. View Article : Google Scholar : PubMed/NCBI

8 

Grosso JF and Jure-Kunkel MN: CTLA-4 blockade in tumor models: An overview of preclinical and translational research. Cancer Immun. 13:52013.PubMed/NCBI

9 

Schwartz JC, Zhang X, Fedorov AA, Nathenson SG and Almo SC: Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature. 410:604–608. 2001. View Article : Google Scholar : PubMed/NCBI

10 

Yu H, Yang J, Jiao S, Li Y, Zhang W and Wang J: Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: Implications for prognosis. Cancer Immunol Immunother. 64:853–860. 2015. View Article : Google Scholar : PubMed/NCBI

11 

Mao H, Zhang L, Yang Y, Zuo W, Bi Y, Gao W, Deng B, Sun J, Shao Q and Qu X: New Insights of CTLA-4 into its biological function in breast cancer. Curr Cancer Drug Targets. 10:728–736. 2010. View Article : Google Scholar : PubMed/NCBI

12 

Salvi S, Fontana V, Boccardo S, Merlo DF, Margallo E, Laurent S, Morabito A, Rijavec E, Dal Bello MG, Mora M, et al: Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer Immunol Immunother. 61:1463–1472. 2012. View Article : Google Scholar : PubMed/NCBI

13 

Kim JW, Nam KH, Ahn SH, Park DJ, Kim HH, Kim SH, Chang H, Lee JO, Kim YJ, Lee HS, et al: Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer. 19:42–52. 2016. View Article : Google Scholar : PubMed/NCBI

14 

Laurent S, Carrega P, Saverino D, Piccioli P, Camoriano M, Morabito A, Dozin B, Fontana V, Simone R, Mortara L, et al: CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions. Hum Immunol. 71:934–941. 2010. View Article : Google Scholar : PubMed/NCBI

15 

Zhang XF, Pan K, Weng DS, Chen CL, Wang QJ, Zhao JJ, Pan QZ, Liu Q, Jiang SS, Li YQ, et al: Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: Implications for prognosis. Oncotarget. 7:26670–26679. 2016.PubMed/NCBI

16 

Ehinger A, Malmström P, Bendahl PO, Elston CW, Falck AK, Forsare C, Grabau D, Rydén L, Stål O and Fernö M; South and South-East Swedish Breast Cancer Groups, : Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013. Acta Oncol. 56:68–74. 2017. View Article : Google Scholar : PubMed/NCBI

17 

Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B and Senn HJ; Panel members, : Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI

18 

Prihantono P, Hatta M, Binekada C, Sampepajung D, Haryasena H, Nelwan B, Asadul Islam A and Nilawati Usman A: Ki-67 expression by immunohistochemistry and quantitative real-time polymerase chain reaction as predictor of clinical response to neoadjuvant chemotherapy in locally advanced breast cancer. J Oncol. 2017:62098492017. View Article : Google Scholar : PubMed/NCBI

19 

Emens LA: Breast cancer immunobiology driving immunotherapy: Vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther. 12:1597–1611. 2012. View Article : Google Scholar : PubMed/NCBI

20 

Koch MA, Thomas KN, Perdue NR, Smigiel KS, Srivastava S and Campbell DJ: T-bet(+) Treg cells undergo abortive Th1 cell differentiation due to impaired expression of IL-12 receptor β2. Immunity. 37:501–510. 2012. View Article : Google Scholar : PubMed/NCBI

21 

Yu HM, Yang JL, Jiao SC, Wang JD and Li Y: TGF-β1 precursor and CD8 are potential prognostic and predictive markers in operated breast cancer. J Huazhong Univ Sci Technolog Med Sci. 34:51–58. 2014. View Article : Google Scholar : PubMed/NCBI

22 

Vonderheide RH, LoRusso PM, Khalil M, Gartner EM, Khaira D, Soulieres D, Dorazio P, Trosko JA, Rüter J, Mariani GL, et al: Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res. 16:3485–3494. 2010. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April 2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Lan, G., Li, J., Wen, Q., Lin, L., Chen, L., Chen, L., & Chen, X. (2018). Cytotoxic T lymphocyte associated antigen 4 expression predicts poor prognosis in luminal B HER2-negative breast cancer. Oncology Letters, 15, 5093-5097. https://doi.org/10.3892/ol.2018.7991
MLA
Lan, G., Li, J., Wen, Q., Lin, L., Chen, L., Chen, L., Chen, X."Cytotoxic T lymphocyte associated antigen 4 expression predicts poor prognosis in luminal B HER2-negative breast cancer". Oncology Letters 15.4 (2018): 5093-5097.
Chicago
Lan, G., Li, J., Wen, Q., Lin, L., Chen, L., Chen, L., Chen, X."Cytotoxic T lymphocyte associated antigen 4 expression predicts poor prognosis in luminal B HER2-negative breast cancer". Oncology Letters 15, no. 4 (2018): 5093-5097. https://doi.org/10.3892/ol.2018.7991